NIH Guide - Vol. 15, No. 26 - November 21, 1986 by NIHhealth

VIEWS: 27 PAGES: 12

									NOTICE OF MAILING 
                     0 Check here if your address has     NIH Guide
CHANGE 
                                  changed and you wish to con­       Distribution Center
                                          tinue receiving this publication   National Institutes of Health
0 Check here if you wish to 

                                          Make corrections below and         Room B3BE07, Building 31
  discontinue receiving this                                                 Bethesda, Maryland 20832
  publication                             mail this page to:



U.S. DEPARTMENT OF HEAEH
                                                                                            Third-ClassMail
AND HUMAN SERVICES                                                                         Postage & Fees Paid
OFFICIAL I3LrSINESS                                                                          PHS/NIH/OD
Penalty for Private Use, $300                                                               Permit No. G-291
The NIH Guide announces scientific
initiatives and provides poliq and
administrative information t o indivi
duals and organizations who need t o
be kept informed ofopponunities,
requirements. and changes in extm­
murd program administered by the
National Institutes of Health.



 VOL. 1 5 , NO. 26, NOVEMBER 21, 1986 

             Vol. 15, No. 26, November 21, 1986                                                            c
                                                        NOTICES 


             PUBLIC HEALTH SERVICE POLICY ON HUMANE CARE AND USE OF LABORATORY 

                  ANIMALS REVISED AS OF SEPTEMBER 1986.......,.............................1

             National Institutes of Health 

             Index: ANIMALS 

             MODIFICATIONS IN THE NRSA SENIOR FELLOWSHIP PROGRAM...........................l 

             National Institutes of Health 

             Index: FELLOWSHIPS 

                                          -
                                  DATED ANNOUNCEMENTS (RFPs AND RFAs AVAILABLE 1

             PROPHYLACTIC PENICILLIN IN SICKLE CELL DISEASE (RFP)...........
             National Heart, Lung, and Blood Institute
                                                                                     ...............2
I            Index: HEART, LUNG, AND BLOOD INSTITUTE
1
             BALLOON VALVULOPLASTY/DATA COORDINATING CENTER (RFP)
             National Heart, Lung, and Blood Institute 

                                                                        ..........................   2 

             Index: HEART, LUNG, AND BLOOD INSTITUTE 

             IDENTIFICATION, ACQUISITION AND PRODUCTION OF REAGENTS AGAINST 

                  H-2 CELL MEMBRANE ANTIGENS (RFP).     ........................................
             National Institute of Allergy and Infectious Diseases
                                                                                                     3
             Index: ALLERGY AND INFECTIOUS DISEASES
             PERFORMANCE OF PROTOCOL TOXICOLOGY STUDIES (RFP)
             National Cancer Institute
                                                                    ..............................   3
’**          Index: CANCER
             APPLICATION OF SUPERCOMPUTERS TO BIOMEDICAL RESEARCH (RFA)....................4

             Division of Research Resources

             Index2 RESEARCH RESOURCES 

             COOPERATIVE AGREEMENTS FOR COOPERATIVE GROUP OUTREACH PROGRAM (RFA)...........4

             National Cancer Institute 

             Index: CANCER 

             COOPERATIVE AGREEMENTS FOR PREVENTION CLINICAL TRIALS UTILIZING
                  INTERMEDIATE ENDPOINTS AND THEIR MODULATION BY CHEMOPREVENTIVE
                  AGENTS (RFA).............................................................          5
             National Cancer Institute 

             Index: CANCER 

             COOPERATIVE AGREEMENTS FOR METABOLISM AND PHYSIOLOGY OF RETINOIDS AND 

                  CAROTENOIDS IN HUMANS (RFA).
             National Cancer Institute
                                                   .............................................     6
             Index: CANCER
             COOPERATIVE AGREEMENTS FOR THE PHYSIOCHEMICAL EFFECTS OF 

                  DIETARY FIBER IN HUMANS (RFA). ...........................................         7
             National Cancer Institute
             Index: CANCER
             CANCER PREVENTION AND CONTROL RESEARCH SMALL GRANTS PROGRAM (RFA)...
             National Cancer Institute 

                                                                                           ..........7

             Index: CANCER 

             DATA-BASED INTERVENTIONS FOR CANCER CONTROL (RFA)....
             National Cancer Institute 

                                                                         .........................   9 

             Index: CANCER 

    ..up 	   SPECIALIZED CENTERS OF RESEARCH IN ADULT RESPIRATORY FAILURE (RFA). ........... 10
             National Heart, Lung, and Blood Institute
             Index: HEART, LUNG, AND BLOOD
                                                                         NOTICES 


            UBLIC H A T SERVICE POLICY ON HUMANE CARE AND
r - y      ESE OF &kR!TORY                   S
                            ANIMALS REVISED A OF SEPTEMBER 1986
'.*q*F,    P.T. 34;        K.W. 0201011, 1014003, 1014002
           National I n s t i t u t e s o f Health 

           The P u b l i c Health S e r v i c e P o l i c y on Humane Care and U s e o f Laboratory Animals (PHS

           P o l i c y ) h a s been amended t o i n c o r p o r a t e changes mandated by t h e Health Research 

           Extension A c t of 1985, P u b l i c Law 99-158.                         The most s i g n i f i c a n t changes a r e : 

           members of t h e I n s t i t u t i o n a l Animal Care and U s e Committee ( I A C U C ) must now be 

           a p p o i n t e d by t h e Chief Executive O f f i c e r (CEO); animal w e l f a r e a s s u r a n c e must now 

           c o n t a i n a n e x p l a n a t i o n o f t r a i n i n g or i n s t r u c t i o n a v a i l a b l e t o a l l p e r s o n n e l 

           involved i n t h e u s e , c a r e r and t r e a t m e n t o f animals; IACUC e v a l u a t i o n s must be 

           conducted once e v e r y s i x months; and m i n o r i t y views o f IACUC members must be 

           i n c l u d e d i n t h e r e p o r t s o f t h e semi-annual reviews. 

           I n s t i t u t i o n s which have an approved or p r o v i s i o n a l l y a c c e p t a b l e Animal Welfare 

           Assurance on f i l e w i t h OPRR must submit by J u l y 1 , 1987 an amendment t o t h e i r 

           a s s u r a n c e which r e f l e c t s t h e changes t h a t t h e i n s t i t u t i o n h a s made t o conform t o t h e 

           amended PHS P o l i c y . 

           Copies o f t h e P u b l i c H e a l t h S e r v i c e P o l i c y on Humane Care and Use o f Laboratory

           Animals Revised a s o f September 1986 may be o b t a i n e d from: 

           C a r o l Young Wigglesworth

           Office f o r P r o t e c t i o n from Research R i s k s 

           National I n s t i t u t e s of Health 

           B u i l d i n g 31, Room 4B09 

           Bethesda, MD 20892 

           Telephone:         (301) 496-7163 


           flODIFICATIONS IN THE NRSA SENIOR FELLOWSHIP P R O G W 

(--   .'   P.T. 22;        K.W. 0720005, 1014002
'.--%ll
    Nationa              I n s t i t u t e s o f Health
           To emphasize t h e t r a i n i n g n a t u r e and i n t e n t o f S e n i o r Fellowships under t h e N a t i o n a l
           Research S e r v i c e Award (NRSA) program, t h e i n f o r m a t i o n s t a t e m e n t d e s c r i b i n g t h e s e
           f e l l o w s h i p s h a s been r e v i s e d (September 1, 1986). The r e v i s e d i n f o r m a t i o n s t a t e m e n t
           now i n c l u d e s t h e f o l l o w i n g :
           "The s e n i o r f e l l o w s h i p i s designed t o p r o v i d e t r a i n i n g f o r experienced s c i e n t i s t s t o
           make major changes i n t h e d i r e c t i o n o f t h e i r r e s e a r c h c a r e e r s , or t o broaden t h e i r
           s c i e n t i f i c backgrounds by a c q u i r i n g new r e s e a r c h c a p a b i l i t i e s . These awards w i l l
           e n a b l e i n d i v i d u a l s beyond t h e new i n v e s t i g a t o r s t a g e t o t a k e time from r e g u l a r
           p r o f e s s i o n a l r e s p o n s i b i l i t i e s f o r t h e purpose o f r e c e i v i n g t r a i n i n g t o i n c r e a s e
           their s c i e n t i f i c c a p a b i l i t i e s to engage i n h e a l t h - r e l a t e d r e s e a r c h . "
           Also, t h e $30,000 maximum s t i p e n d i s s p e c i f i e d as a 12-month s t i p e n d t o be p r o r a t e d
           f o r t r a i n i n g p e r i o d s o f l e s s t h a n 12 months. The modified g u i d e l i n e s w i l l a p p l y t o
           a p p l i c a t i o n s s u b m i t t e d for t h e January 10, 1987, and subsequent r e c e i p t d a t e s .
           The r e v i s e d s e n i o r f e l l o w s h i p i n f o r m a t i o n s t a t e m e n t i s now b e i n g s e n t o u t w i t h
           a p p l i c a t i o n k i t s . A d d i t i o n a l c o p i e s a r e a v a i l a b l e from:
           Program Analyst                                    O f f i c e o f Grants I n q u i r i e s
           Manpower Review S e c t i o n                      D i v i s i o n o f Research Grants
           D i v i s i o n o f Research G r a n t s           Westwood B u i l d i n g , Room 449
           Westwood B u i l d i n g , Room A27                N a t i o n a l I n s t i t u t e s o f Health
           N a t i o n a l I n s t i t u t e s o f Health     Bethesda, Maryland 20892
           Bethesda, Maryland 20892                           Telephone:            ( 3 0 1 ) 496-7441
           Telephone:            ( 3 0 1 ) 496-7221




                                                                               1
                                     DATED ANNOUNCEMENTS (RFPs AND RFAs AVAILABLE)

      PROPHYLACTIC PENICILLIN I N SICKLE CELL DISEASE 

      RFP AVAILABLE:            RFP-NHLBI-HB-87-08 

                                                                                                                                                      -

      P.T. 34;        K.W.    0755015, 0740005, 0745055 

      N a t i o n a l Heart, Lung, and Blood I n s t i t u t e 

      The S i c k l e C e l l Disease Branch o f t h e D i v i s i o n o f Blood Diseases and Resources o f 

      t h e N a t i o n a l Heart, Lung, and Blood I n s t i t u t e p l a n s t o e v a l u a t e t h e b e n e f i t l r i s k o f 

      d i s c o n t i n u i n g d a i l y o r a l p e n i c i l l i n a t t h e age o f f i v e y e a r s i n c h i l d r e n w i t h s i c k l e 

      c e l l d i s e a s e . The o f f e r o r must c o n t a c t and e n t e r i n t o t h e s t u d y p a t i e n t s w i t h t h e 

      f o l l o w i n g c h a r a c t e r i s t i c s : C h i l d r e n w i t h s i c k l e c e l l anemia who a r e f i v e y e a r s and 

      t h r e e months o f age or l e s s ; who w i l l have been on o r a l p e n i c i l l i n p r o p h y l a x i s 

      f o r a t l e a s t two y e a r s by t h e t i m e o f randomization; whose b i r t h d a t e s are n o t 

      l a t e r t h a n J a n u a r y 1, 1987; and whose p a r e n t s / g u a r d i a n s consent t o immediate e n t r y 

      o f t h e i r c h i l d r e n and a l s o randomization a t age f i v e i n t o a group t o c o n t i n u e o r a l 

      p e n i c i l l i n or a group t o s t o p p r o p h y l a x i s . A minimum o f t e n ( 1 0 ) c h i l d r e n must be 

      a v a i l a b l e f o r e n t r y and follow-up f o r t h e s t u d y which i n v o l v e s : c o l l e c t i o n o f 

      c l i n i c a l d a t a a t s p e c i f i e d i n t e r v a l s , e . g . , h i s t o r y , p h y s i c a l exam, N c u l t u r e s , 

                                                                                                                             P
      c u l t u r e s w i t h i n f e c t i o n , a n t i b o d y l e v e l s , e t c . T h i s i s an announcement f o r a 

      Request f o r P r o p o s a l s (RFP). RFP NIH-NHLBI-HE-87-08                                w i l l be a v a i l a b l e on or about 

      November 21, 1986. T h i s i s a seven-year program. Twenty t o f o r t y awards a r e 

      a n t i c i p a t e d by t h e Government. Your w r i t t e n r e q u e s t should i n c l u d e t h r e e (3)

      s e l f - a d d r e s s e d m a i l i n g l a b e l s , and m u s t c i t e RFP No. NHLBI-HB-87-08. 

      Request f o r c o p i e s o f t h e RFP should be s e n t t o t h e f o l l o w i n g a d d r e s s : 

      Lynda A . B i n d s e i l , C o n t r a c t S p e c i a l i s t 

      BDR C o n t r a c t s S e c t i o n 

      N a t i o n a l Heart, Lung, and Blood I n s t i t u t e 

      F e d e r a l Bldg., Room 5C14 

      7550 Wiscorssin Avenue 

      Bethesda, MD 20892 



cY
      BALLOON VALWLOPLASTY/DATA COORDINATING CENTER

      RFP AVAILABLE:
      P.T. 34;        K.W.
                                RFP-NHLBI-HV-87-03 

                               1010013, 1004008 

                                                                                                                                                      c
      N a t i o n a l Heart, Lung, and Blood I n s t i t u t e 

      The N a t i o n a l Heart, Lung, and Blood I n s t i t u t e ( N H L B I ) r e q u i r e s an o r g a n i z a t i o n t o 

      f u n c t i o n as a Data C o o r d i n a t i n g Center d u r i n g t h e f i v e y e a r p e r i o d from J u n e 1987 t o 

      June 1992 t o c o l l e c t , e d i t , s t o r e , and a n a l y z e b a s e l i n e and outcome d a t a on p a t i e n t s 

      with severe valvular s t e n o s i s t r e a t e d with balloon valvuloplasty at various 

      p a r t i c i p a t i n g centers. To accomplish t h i s o b j e c t i v e t h e c o n t r a c t o r w i l l be r e q u i r e d 

      to:       ( 1 ) Work w i t h i n v e s t i g a t o r s from t h e C l i n i c a l U n i t s and t h e Cardiac Diseases 

      Branch s t a f f , NHLBI, i n development o f a f i n a l s t u d y p r o t o c o l , manual o f o p e r a t i o n s , 

      and d a t a forms (Phase I ) ; ( 2 ) C o l l e c t , e d i t , s t o r e , and analyze d a t a s u b m i t t e d from 

      t h e C l i n i c a l U n i t s (Phase I I l p a t i e n t a c c r u a l ) ; and (3) Monitor submission o f 

      follow-up d a t a and p r o v i d e a n a l y s e s and e x p e r t s t a t i s t i c a l a d v i c e r e g a r d i n g 

      p u b l i c a t i o n of s t u d y f i n d i n g s (Phase 111). 

      T h i s i s n o t a Request f o r P r o p o s a l s (RFP). RFP NIH-NHLBI-HV-87-03                         w i l l be a v a i l a b l e 

      on or about November 25, 1986, w i t h p r o p o s a l s due on o r about J a n u a r y 12, 1987. One 

      ( 1 ) award i s a n t i c i p a t e d by t h e Government. Your w r i t t e n r e q u e s t should i n c l u d e 

      t h r e e (3) l a b e l s , s e l f - a d d r e s s e d w i t h your m a i l i n g a d d r e s s , and must c i t e RFP No. 

      NHLBI-HV-87-03. 

      Request f o r c o p i e s o f t h e RFP s h o u l d be s e n t t o t h e f o l l o w i n g a d d r e s s : 

      Kristee M . Ryman, C o n t r a c t S p e c i a l i s t 

      HVD C o n t r a c t s S e c t i o n , C o n t r a c t s O p e r a t i o n s Branch, DEA 

      N a t i o n a l Heart, Lung, and Blood I n s t i t u t e 

      F e d e r a l B u i l d i n g , Room 4C04 

      National I n s t i t u t e s of Health 

      Bethesda, Maryland 20892 

‘kl




                                                                          2 

-
IDENTIFICATION,      ACQUISITION AND PRODUCTION OF REAGENTS AGAINST
-
H-2      CELL MEMBRANE ANTIGENS
RFP AVAILABLE:            RFP-NIH-NIAID-IAIDP-87-22
F     ..   34;   K.W. 0740020, 1003006, 0760045
 b0
N a t i o n a l I n s t i t u t e o f A l l e r g y and I n f e c t i o u s Diseases 

The N a t i o n a l I n s t i t u t e s of H e a l t h ( N I H ) h a s a requirement for t h e a c q u i s i t i o n of 

r e a g e n t s a g a i n s t H-2 c e l l membrane a n t i g e n s and t h e corresponding immunogens. 

The G e n e t i c s and T r a n s p l a n t a t i o n Biology Branch o f t h e Immunology, A l l e r g y and 

Iminunologic Diseases Program o f t h e N a t i o n a l I n s t i t u t e o f A l l e r g y and I n f e c t i o u s 

D i s e a s e s ( N I A I D ) is s o l i c i t i n g c o n t r a c t p r o p o s a l s from o r g a n i z a t i o n s having t h e 

f a c i l i t i e s and demonstrated e x p e r t i s e i n s y n t h e s i s of p o l y - p e p t i d e s and p r e p a r a t i o n 

of monoclonal a n t i b o d i e s a n d l o r x e n o a n t i s e r a . 

T h i s N I A I D sponsored p r o j e c t s h a l l t a k e approximately f i v e y e a r s t o complete. The 

work w i l l r e q u i r e p o l y p e p t i d e s y n t h e s i s , Mab and/or x e n o a n t i s e r a p r e p a r a t i o n and 

c h a r a c t e r i s t i z a t i o n , a s w e l l as t h e a c q u i s i t i o n o f r e a g e n t s p r e p a r e d by o t h e r 

i n v e s t i g a t o r s . Access t o a w e l l maintained i n b r e d mouse colony and/or f a c i l i t i e s 

n e c e s s a r y f o r t h e p r e p a r a t i o n o f x e n o a n t i s e r a is r e q u i r e d . 

T h i s i s a n announcement f o r a n a n t i c i p a t e d Request f o r Proposal (RFP).

RFP-NIH-NIAID-IAIDP-87-22 w i l l be i s s u e d on or about November 26, 1986, w i t h a 

c l o s i n g d a t e t e n t a t i v e l y s e t for January 21, 1987. T h i s w i l l be a c o s t 

reimbursement c o n t r a c t . One award i s a n t i c i p a t e d as a r e s u l t o f t h i s announcement. 

Requests f o r t h e RFP should be d i r e c t e d i n writing t o r 

Larry Butler 

C o n t r a c t S p e c i a l i s t , C o n t r a c t Management Branch 

N a t i o n a l I n s t i t u t e o f A l l e r g y and I n f e c t i o u s Diseases 

National I n s t i t u t e s of Health 

Westwood B u i l d i n g , Room 707 

5333 West b a r d Avenue 

Bethesda, Maryland 20892 

Tt         a d v e r t i s e m e n t does n o t commit t h e Government t o award a c o n t r a c t . 

    -0

PERFORMANCE OF PROTOCOL TOXICOLOGY STUDIES
RFP AVAILABLE: NCI-CM-87201-29
P.T. 34;         K.W. 1007009, 07101001 0740020
N a t i o n a l Cancer I n s t i t u t e
The Development T h e r a p e u t i c s Program (DTP) o f t h e D i v i s i o n o f Cancer Treatment
(DCI'), N a t i o n a l Cancer I n s t i t u t e (NCI), i s s e e k i n g o r g a n i z a t i o n s to conduct, under
c o n t r a c t , p r e - c l i n i c a l t o x i c o l o g y s t u d i e s of o n c o l i t i c a g e n t s . The d a t a from t h e s e
stuldies must be s u i t a b l e f o r f i l i n g w i t h t h e Food and Drug A d m i n i s t r a t i o n (FDA) as
p a r t o f I n v e s t i g a t i o n a l N e w Drug A p p l i c a t i o n s ( I N D A ) .       The o r g a n i z a t i o n s should have
t h e f a c i l i t i e s and s t a f f t o c a r r y o u t such s t u d i e s and t h e management e x p e r t i s e t o
a n a l y z e and e v a l u a t e t h e d a t a .
A s .a minimum requirement, t h e C o n t r a c t o r s must perform a l l t o x i c o l o g y s t u d i e s i n
accordance w i t h t h e FDA's Good Laboratory P r a c t i c e R e g u l a t i o n s (GLP's).                        Contractors
must b e i n compliance w i t h GLP's a t t h e t i m e o f p r o p o s a l submission. M u l t i p l e (2-4)
c o n t r a c t s w i l l be awarded and each w i l l be a d m i n i s t e r e d on a t a s k managed b a s i s .
Taslk o r d e r s w i l l be i s s u e d under funded cost-reimbursement, l e v e l - o f - e f f o r t
c o n t r a c t s r e s u l t i n g from t h i s s o l i c i t a t i o n . Annual workload e s t i m a t e d for t h e
d e s c r i b e d s t u d i e s are 8 , 0 0 0 t e c h n i c a l s t a f f h o u r s p e r y e a r compound s t u d i e d .
Assignments are e s t i m a t e d t o i n v o l v e 2-4 a g e n t s p e r y e a r . The o b j e c t i v e o f t h e t a s k
orders t o be i s s u e d a r e : d e t e r m i n a t i o n and s a f e t y assessment of an i n i t i a l dose f o r
c l i n i c a l use; and d e t e r m i n a t i o n of t h e primary organ systems a d v e r s e l y a f f e c t e d by
t h e drug a d m i n i s t r a t i o n ; d e t e r m i n a t i o n o f s c h e d u l e dependent t o x i c i t y ; and
a c q u i s i t i o n and use of pharmacokinetic i n f o r m a t i o n t o p e r m i t e x t r a p o l a t i o n o f t o x i c
e f f e c t s a c r o s s species by r e l a t i n g plasma d r u g l e v e l s t o t i m e of appearance and
s e v e r i t y of toxicity.




                                                                   3

      me p r i n c i p a l I n v e s t i g a t o r should have a d o c t o r a l d e g r e e i n toxicology/pharmacology
      o r a c l o s e l y r e l a t e d d i s c i p l i n e and s e v e r a l y e a r s o f d i v e r s e e x p e r i e n c e i n
      d i r e c t i n g , implementing and e v a l u a t i n g p r e c l i n i c a l d r u g t o x i c i t y s t u d i e s i n
      e x p e r i m e n t a l a.nimals. The p a t h o l o g i s t and a n a l y t i c a l chemist should s i m i l a r l y have
      c r e d e n t i a l s d e m o n s t r a t i n g competence and accomplishments i n s e r v i n g a s c r i t i c a l team
      members i n t h e conduct o f such s t u d i e s .
      It i s a n t i c i p a t e d t h a t c o n t r a c t awards w i l l c o v e r a p e r i o d o f f i v e y e a r s and t h e y
      w i l l b e i n c r e m e n t a l l y funded. The s o l i c i t a t i o n r e p r e s e n t s a r e c o m p e t i t i o n o f work
      done i n p a r t under a prime c o n t r a c t c u r r e n t l y h e l d by B a t t e l l e Memorial I n s t i t u t e ,
      Columbus L a b o r a t o r i e s , Columbus, Ohio.
      A l l r e s p o n s i b l e s o u r c e s may submit a p r o p o s a l which w i l l be c o n s i d e r e d by t h e
      N a t i o n a l Cancer I n s t i t u t e .
      T h i s s y n o p s i s is n o t a r e q u e s t f o r p r o p o s a l (RFP). It i s a n t i c i p a t e d t h e RFP
      NCI-CM-87201-29 f o r t h e above d e s c r i b e d work w i l l be a v a i l a b l e t o i n t e r e s t e d
      o f f e r o r s on or about J a n u a r y 15, 1987, w i t h a c l o s i n g d a t e f o r r e c e i p t o f p r o p o s a l s
      on March 2, 1987. Copies o f t h e RFP may b e o b t a i n e d by sending a w r i t t e n r e q u e s t
      to:
      Clyde W i l l i a m s 

      C o n t r a c t i n g Officer 

      Treatment C o n t r a c t s S e c t i o n 

      Research C o n t r a c t s Branch, OD 

      N a t i o n a l Cancer I n s t i t u t e 

      B l a i r B u i l d i n g , Room 224 

      Bethesda, Maryland 20892 


      APPLICATION OF SUPERCOMPUTERS T BIOME DICAL 
 RESEARCH

                                     O
      RFA AVAILABLE:            87-RR-01 

      P.T. 34;        K.W. 1004000, 0780000, 0720005 

      D i v i s i o n o f Research Resources 

      A p p l i c a t i o n R e c e i p t Date:   February 23, 1987 

      The Biomedical Research Technology Program, D i v i s i o n o f Research Resources, i n v i t e s 

      a p p l i c a t i o n s f o r a c o o p e r a t i v e agreement t o s u p p o r t a c t i v i t i e s designed t o i n t r o d u c e 

      biomedical s c i e n t i s t s t o supercomputer c a p a b i l i t i e s by p r o v i d i n g access t o 

      supercomputers and t o t r a i n t h e s e s c i e n t i s t s i n t h e u s e o f supercomputers. 

      The purpose o f t h e RFA i s t o s o l i c i t a p p l i c a t i o n s from q u a l i f i e d i n s t i t u t i o n s w i t h 

      supercomputer f a c i l i t i e s on s i t e and who a r e i n t e r e s t e d i n p r o v i d i n g biomedical 

      s c i e n t i s t s access t o t h e s e supercomputer c a p a b i l i t i e s , t r a i n i n g t h e s e s c i e n t i s t s i n 

      t h e u s e of supercomputers, and e v a l u a t i n g t h e r e s u l t s o f t h e s e e f f o r t s . 

      A copy o f t h e f u l l Request f o r A p p l i c a t i o n s announcement may be o b t a i n e d from: 

      Suzanne S. S t i m l e r , Ph.D. 

      D i r e c t o r , Biomedical Research Technology Program

      D i v i s i o n 'of Research Resources 

      National I n s t i t u t e s o f Health 

      B u i l d i n g 31, Room 5841 


      COOPERATIVE AGREEMENTS FOR COOPERATIVE GROUP OUTREACH P O R M

                                                             RGA
      RFA AVAILABLE:            87-CA-07
      P.T.    34;     K.W. 0755015, 0403004, 0715035, 0415000, 0710100, 1007009
      N a t i o n a l Cancer I n s t i t u t e
      L e t t e r o f I n t e n t R e c e i p t Date:   December 15, 1986
      A p p l i c a t i o n R e c e i p t Date:    February 20, 1987
      The N a t i o n a l Cancer Institute (NCI) i n v i t e s c o o p e r a t i v e agreement a p p l i c a t i o n s from
      e x i s t i n g NCI-supported C l i n i c a l T r i a l s Cooperative Groups f o r t h e purpose of
      e x t e n d i n g t h e ongoing c l i n i c a l t r i a l s program t o i n c l u d e community h o s p i t a l s and I
      p h y s i c i a n s . T h i s RFA i s a modified r e i s s u a n c e o f RFA 84-CA-04.                                k,
P I                                                                                                                                            -.



                                                                       4 

       A major g o a l o f t h e D i v i s i o n of Cancer Treatment, N C I i s t h e d e s i g n and e v a l u a t i o n
       of e f f e c t i v e methods o f c a n c e r t h e r a p y . T h i s h a s been implemented p r i m a r i l y through
       t h e C l i n i c a l Cooperative Groups which, through t h e i r broad r e p r e s e n t a t i o n w i t h i n t h e
       academic c l i n i c a l oncology community, have s u c c e s s f u l l y pursued t h i s o b j e c t i v e a t
       t h e major medical c e n t e r s a c r o s s t h e c o u n t r y . A s most c a n c e r p a t i e n t s p r e f e r t o be
       t r e a t e d i n t h e i r l o c a l s e t t i n g s , t h e Cooperative Group Outreach Program was
-*.* 	 developed t o e x t e n d t h e c l i n i c a l t r i a l s program so t h a t p a t i e n t s t r e a t e d i n t h e i r
       communities have access t o t h e same q u a l i t y c a r e and t e c h n o l o g i c a l advances
       a v a i l a b l e i n major t r e a t m e n t c e n t e r s . The C l i n i c a l T r i a l s Cooperative Groups, w i t h
       t h e i r widely d i s t r i b u t e d membership, a f f o r d a means o f m a i n t a i n i n g a network of 

       community p h y s i c i a n s i n t e r e s t e d i n p a r t i c i p a t i n g i n c l i n i c a l c a n c e r r e s e a r c h . T h i s 

       program h a s developed i n t o a major s o u r c e o f p a t i e n t a c c r u a l s t o c o o p e r a t i v e 

       c l i n i c a l t r i a l s , t h u s p r o v i d i n g more r a p i d and d e f i n i t i v e answers t o important

       c l i n i c a l r e s e a r c h q u e s t i o n s which r e q u i r e l a r g e numbers o f p a t i e n t s . N C I i s 

       t h e r e f o r e i n v i t i n g a p p l i c a t i o n s from t h e h e a d q u a r t e r s or s t a t i s t i c a l o f f i c e o f 

       NCI-supported C l i n i c a l T r i a l s Cooperative Groups t o c o n t i n u e l e x t e n d t h e Cooperative

       Group Outreach Program. 

         A p p l i c a n t s are s t r o n g l y encouraged t o submit by December 15, 1986, a l e t t e r of 

         i n t e n t and t o c o n s u l t w i t h N C I program s t a f f p r i o r t o developing an a p p l i c a t i o n 

         because o f t h e need for a c l e a r u n d e r s t a n d i n g o f t h e o b j e c t i v e s o f t h e program and 

         f o r a p p r o p r i a t e p l a n n i n g f o r t h e review o f t h e a p p l i c a t i o n s . A t o t a l o f f o u r 

         m i l l i o n d o l l a r s w i l l be a v a i l a b l e f o r FY87 awards. It i s a n t i c i p a t e d t h a t about 

         seven awards w i l l b e made as a r e s u l t of t h i s RFA. 

         Complete c o p i e s o f t h i s RFA (87-CA-07)                 may be o b t a i n e d from: 

         Richard S . U n g e r l e i d e r , M . D . 

         Cancer Therapy E v a l u a t i o n Program

         D i v i s i o n of Cancer Treatment, N C I 

         Landow B u i l d i n g , Room 4A20 

         Bethesda, MD 20892 

         Telephone:         (301) 496-2522 


         COOPERAT I E AGREEMENTS FOR PREVENTION CLINICAL TRIALS UTILIZING
         J                                                                GEN S
  ,      RFA AVAILABLE: 87-CA-11
         P.T. 34;        K.W. 0755015, 0745055, 0740020
         N a t i o n a l Cancer I n s t i t u t e
         A p p l i c a t i o n Receipt Date:         J a n u a r y 3 0 , 1987
         The D i v i s i o n o f Cancer P r e v e n t i o n and C o n t r o l (DCPC), N a t i o n a l Cancer I n s t i t u t e
         ( N C I ) , i n v i t e s a p p l i c a t i o n s f o r c o o p e r a t i v e agreements t o s u p p o r t c l i n i c a l t r i a l s
         which are d i r e c t e d toward examining t h e r o l e o f v a r i o u s chemopreventive a g e n t s
         and/or d i e t i n t h e p r e v e n t i o n o f c a n c e r . T h i s i s a follow-up t o e a r l i e r RFAs which
         had r e q u e s t e d g r a n t s , and t h e n l a t e r , c o o p e r a t i v e agreement p r o p o s a l s i n t h i s area.
         The major o b j e c t i v e of t h i s s o l i c i t a t i o n is t o encourage c a n c e r chemoprevention
         c l i n i c a l t r i a l s which u t i l i z e biochemical and b i o l o g i c a l markers t o i d e n t i f y
         p o p u l a t i o n s a t r i s k and/or t o p r o v i d e i n t e r m e d i a t e e n d p o i n t s t h a t may p r e d i c t l a t e r
         reduction i n cancer incidence r a t e s .
         These s t u d i e s should be developed i n phases, i n c l u d i n g a p i l o t phase, which c o u l d
         l a t e r proceed t o a f u l l scale i n t e r v e n t i o n . The main emphasis should be on s m a l l ,
         e f f i c i e n t s t u d i e s aimed a t improving f u t u r e r e s e a r c h d e s i g n s o f chemoprevention
         t r i a l s , p r o v i d i n g b i o l o g i c u n d e r s t a n d i n g o f what i s happening i n t h e t r i a l s , or
         p r o v i d i n g b e t t e r , more q u a n t i t a t i v e and more e f f i c i e n t e n d p o i n t s f o r t h e s e t r i a l s .
         A f t e r s u c c e s s f u l completion o f t h e p i l o t phase; ( i . e . demonstrated modulation of
         marker e n d p o i n t s by t h e i n t e r v e n t i o n ) , subsequent s t u d i e s w i l l i n c l u d e Phase I11
         c l i n i c a l t r i a l s involving t h e designated agent, t h e u t i l i z a t i o n of t h e monitoring
         t e s t system and a c a n c e r i n c i d e n c e or m o r t a l i t y endpoint may be implemented.
         I n v e s t i g a t o r s may a p p l y a t t h i s t i m e f o r t h e p i l o t phase, or submit an a p p l i c a t i o n
         f o r b o t h p h a s e s . However, i f t h e a p p l i c a t i o n i s for t h e p i l o t phase o n l y , t h e
         proposed s t u d y m u s t be r e l e v a n t t o a c l i n i c a l a p p l i c a t i o n and u t i l i z e a
         chemopreventive a g e n t , marker t e s t system, and s t u d y p o p u l a t i o n which could l a t e r be
         t h e subject of a full scale, double-blind, randomized, r i s k r e d u c t i o n , c l i n i c a l
         trial.
   I

      Plr,




                                                                            5
            A p p l i c a n t s funded under t h i s RFA w i l l be s u p p o r t e d through t h e c o o p e r a t i v e agreement
            mechanism. An a s s i s t a n c e r e l a t i o n s h i p w i l l e x i s t between N C I and t h e awardees t o
            accomplish t h e purpose o f t h e a c t i v i t y . A s more f u l l y d e s c r i b e d i n t h e


%aJr 	
            announcement, t h e r e c i p i e n t s w i l l have primary r e s p o n s i b i l i t y for t h e development
            and performance o f t h e a c t i v i t y . However, t h e r e w i l l be government involvement w i t h
            r e g a r d t o ( 1 ) a s s i s t a n c e s e c u r i n g an I n v e s t i g a t i o n a l New Drug ( I N D ) approval from
            t h e Food and Drug A d m i n i s t r a t i o n (FDA), ( 2 ) monitoring o f s a f e t y and t o x i c i t y and,
            ( 3 ) c o o r d i n a t i o n and a s s i s t a n c e i n o b t a i n i n g t h e chemopreventive a g e n t , ( 4 ) q u a l i t y
            a s s u r a n c e w i t h r e g a r d t o t h e c l i n i c a l c h e m i s t r y a s p e c t s o f t h e s t u d y . Awards w i l l
            n o t be made u n t i l a l l arrangements for o b t a i n i n g t h e I N D , a g e n t , and i t s d e l i v e r y
                                                                                                                                                          c
            a r e completed. F i n a l awards w i l l a l s o c o n s i d e r n o t o n l y t h e c o s t o f t h e c l i n i c a l
            t r i a l b u t a l s o t h e c o s t o f t h e a g e n t and i t s f o r m u l a t i o n i f n e c e s s a r y .
            T h i s RFA s o l i c i t a t i o n r e p r e s e n t s a s i n g l e c o m p e t i t i o n , with a s p e c i f i e d d e a d l i n e of
            J a n u a r y 3 0 , 1987, for r e c e i p t of a p p l i c a t i o n s . A l l a p p l i c a t i o n s r e c e i v e d i n
            r e s p o n s e t o t h e RFA w i l l be reviewed by t h e same N a t i o n a l I n s t i t u t e s of Health ( N I H )
            I n i t i a l Review Group ( IRG 1          .
            To e n s u r e t h e i r review, a p p l i c a t i o n s should be r e c e i v e d by January 3 0 , 1 9 8 7 .
            A p p l i c a t i o n s r e c e i v e d a f t e r t h a t d a t e w i l l n o t be c o n s i d e r e d under t h i s RFA.
            I n q u i r i e s may be d i r e c t e d t o r
            Winfred Malone, Ph.D.
            Chemoprevention Branch
            Blair Building           -
                                     Room 616
            N a t i o n a l Cancer I n s t i t u t e
            Bethesda, Md. 20892-4200
            Telephones ( 3 0 1 ) 4 2 7 - 8 6 8 0

            COOPERATIVE AGREEMENTS FOR METABOLISM AND PHYSIOLOGY OF RETINOIDS AND 

            CAROTENOIDS I N HUMANS
            RFA AVAILABLE:            87-CA-12
            P.T. 34;        Y.W.     0765020, 1002034, 0710095
            N a t i o n a l Cancer I n s t i t u t e
  -9        A p p l i c a t i o n R e c e i p t Dater   February 2 3 , 1987
            The D i v i s i o n of Cancer P r e v e n t i o n and C o n t r o l (DCPC), N a t i o n a l Cancer I n s t i t u t e 

            ( N C I ) , i n v i t e s a p p l i c a t i o n s f o r c o o p e r a t i v e agreements t o s u p p o r t r e s e a r c h on human 

            metabolism and p h y s i o l o g i c e f f e c t s of r e t i n o i d s and c a r o t e n o i d s . S t u d i e s of 

            i n t e r e s t i n c l u d e metabolism i n t h e i n t e s t i n a l mucosa, i n t e s t i n a l a b s o r p t i o n , 

            r e g u l a t i o n o f g a s t r o i n t e s t i n a l uptake and t i s s u e c o n c e n t r a t i o n s , and 

            e x t r a - i n t e s t i n a l metabolism o f t h e s e compounds. The s t u d i e s should span a range o f 

            d i e t a r y i n t a k e s . The proposed r e s e a r c h r e q u i r e s i n n o v a t i v e approaches t o determine 

            t h e dynamics of a b s o r p t i o n and metabolism, t a r g e t t i s s u e l e v e l s , and s p e c i f i c i t i e s 

            of t h e v a r i o u s v i t a m i n A compounds and how t h e s e d e t e r m i n a t i o n s would e l u c i d a t e t h e 

            r o l e s o f d i e t a r y r e t i n o i d s and c a r o t e n o i d s i n c e l l u l a r i n t e g r i t y and r e s i s t a n c e t o 

            tumor promotion. The l o n g term o b j e c t i v e o f t h i s r e s e a r c h i s t o f u r t h e r t h e 

            u n d e r s t a n d i n g of t h e p h y s i o l o g i c a l e f f e c t s o f r e t i n o i d s and c a r o t e n o i d s i n humans i n 

            o r d e r t o h e l p c l a r i f y t h e s u s p e c t e d r e l a t i o n s h i p t h a t t h e s e s u b s t a n c e s have w i t h 

            human c a n c e r . 

            A p p l i c a n t s funded under t h i s RFA w i l l be supported through t h e c o o p e r a t i v e agreement

            mechanism. A n assistance r e l a t i o n s h i p w i l l e x i s t between N C I and t h e awardees to 

            accomplish t h e purpose o f t h e a c t i v i t y . A s more completely d e s c r i b e d i n t h e 

            announcement, t h e r e c i p i e n t s w i l l have primary r e s p o n s i b i l i t y for t h e development

            and conduct o f t h e r e s e a r c h . N C I involvement w i l l be i n r e g a r d t o c o o r d i n a t i n g and 

            s y n t h e s i z i n g t h e r e s e a r c h e f f o r t i n r e g a r d t o approaches, methodologies and exchange

            o f information. 

            Copies of t h e complete Request for A p p l i c a t i o n s and a d d i t i o n a l i n f o r m a t i o n may be 

            o b t a i n e d from: 

            E l a i n e Lanza, Ph.D. 

            D i e t and Cancer Branch 

            B l a i r Bldg., Rm. 623 

            National Cancer I n s t i t u t e 

            Bethesda, MD 20892 

            Telephone:  ( 3 0 1 ) 427-8753 

     Phwl




                                                                               6
           COOPERATIVE A GREEMENTS FOR THE PHYSIOCHEMICAL EFFECTS OF DIETARY FIBER I N H M N
                                                                                        U AS
           RFA AVAILABLE:            87-CA-13
           P.T. 34;        K.W. 0710095, 0715035, 0745055
46   .J'   N a t i o n a l Cancer I n s t i t u t e
           A p p l i c a t i o n R e c e i p t Date:    J a n u a r y 3 0 , 1987 

           The D i v i s i o n o f Cancer P r e v e n t i o n and C o n t r o l (DCPC), Nation a1 Cancer I n s t i t u t e 

           ( N C I ) , i n v i t e s a p p l i c a t i o n s f o r c o o p e r a t i v e agreements t o s u p p o r t r e s e a r c h on t h e 

           p h y s i c a l , chemical and b i o l o g i c e f f e c t s of d i e t a r y f i b e r s and t h e i r p o s s i b l e 

           protective r o l e i n carcinogenesis. Studies of potential i n t e r e s t t o NCI include,

           b u t a r e n o t l i m i t e d t o , t h e e f f e c t s o f f i b e r on; (1) fecal mutagenic a c t i v i t y , ( 2 ) 

           b i l e a c i d s , and (3) c o l o n c e l l k i n e t i c s , morphology, and physiology i n o r d e r t o 

           f u r t h e r understand t h e r e l a t i o n s h i p between d i e t a r y f i b e r and colon c a n c e r . S t u d i e s 

           r e q u e s t e d under t h i s RFA are l i m i t e d t o t h o s e i n v o l v i n g human s u b j e c t s . A p p l i c a n t s 

           funded under t h i s RFA w i l l be s u p p o r t e d through t h e c o o p e r a t i v e agreement mechanism. 

           An a s s i s t a n c e r e l a t i o n s h i p w i l l e x i s t between N C I and t h e awardees t o accomplish t h e 

           purpose o f t h e a c t i v i t y . A s more completely d e s c r i b e d i n t h e RFA, t h e r e c i p i e n t s 

           w i l l have primary r e s p o n s i b i l i t y f o r t h e development and conduct o f t h e r e s e a r c h 

           w i t h c o o p e r a t i o n and a s s i s t a n c e from N C I s t a f f . Copies o f t h e complete Request f o r 

           A p p l i c a t i o n s and a d d i t i o n a l i n f o r m a t i o n may be o b t a i n e d from: 

           E l a i n e Lanza, Ph.D. 

           D i e t and Cancer Branch 

           B l a i r Bldg., Rm 623 

           N a t i o n a l Cancer I n s t i t u t e 

           Bethesda, MD 20892 

           Telephone:         ( 3 0 1 ) 427-8753 

           To e n s u r e t h e i r review, a p p l i c a t i o n s should be r e c e i v e d by 01/30/87. 


           CANCER PREVENTION AND CONTROL RESEARCH SMALL GRANTS PROGRAM

           RFA AVAILABLE:            87-CA-14 

           P.T. 34;        K.W. 0745035, 0745055, 0403004, 0404019, 0785055 

           N a t i o n a l Cancer I n s t i t u t e 

           Application Receipt D a t e :                March 5, 1987 

           The D i v i s i o n o f Cancer P r e v e n t i o n and C o n t r o l (DCPC) o f t h e N a t i o n a l Cancer 

           I n s t i t u t e ( N C I ) i n v i t e s Small Grant Research a p p l i c a t i o n s from i n t e r e s t e d 

           i n v e s t i g a t o r s who meet t h e e l i g i b i l i t y c r i t e r i a n o t e d below. T h i s RFA i s a modified 

           r e i s s u a n c e o f RFA 86-CA-02; t h e t h r e e p r i o r Small Grant RFAs have r e s u l t e d i n 44 

           awards. F u t u r e p l a n s are t o i s s u e t h i s RFA a t l e a s t a n n u a l l y f o r f i v e y e a r s , w i t h 

           up t o 30 awards p e r y e a r i f funds a r e a v a i l a b l e . 

           RESEARCH GOALS AND SCOPE
           A Cancer P r e v e n t i o n and C o n t r o l Research Small G r a n t s Award i s designed t o encourage
           s c i e n t i s t s from a v a r i e t y o f academic d i s c i p l i n e s t o a p p l y t h e i r s k i l l s t o
           s c i e n t i f i c i n v e s t i g a t i o n s i n t h e f i e l d o f human c a n c e r c o n t r o l i n t e r v e n t i o n
           research.
           DEFINITION AND PHASES OF CANCER CONTROL RESEARCH
           Cancer c o n t r o l i s d e f i n e d a s t h e r e d u c t i o n o f c a n c e r i n c i d e n c e , m o r b i d i t y , and
           m o r t a l i t y through an o r d e r l y sequence from r e s e a r c h on i n t e r v e n t i o n s and t h e i r
           impact i n d e f i n e d p o p u l a t i o n s t o t h e broad, s y s t e m a t i c a p p l i c a t i o n of t h e r e s e a r c h
           results.
           Cancer c o n t r o l r e s e a r c h s t u d i e s are c l a s s i f i e d i n t o one o f f i v e phases which
           r e p r e s e n t t h e o r d e r l y p r o g r e s s i o n noted i n t h e above d e f i n i t i o n :            ( I ) hypothesis
           development; (11) methods development and t e s t i n g ; (111) c o n t r o l l e d i n t e r v e n t i o n
           t r i a l s t o e s t a b l i s h cause and e f f e c t r e l a t i o n s h i p s ; ( I V ) r e s e a r c h i n d e f i n e d , human
           p o p u l a t i o n s ; and (VI demonstration and implementation s t u d i e s . The D i v i s i o n i s
           p r i m a r i l y i n t e r e s t e d i n r e s e a r c h on c a n c e r c o n t r o l i n t e r v e n t i o n s i n Phases I1
           through V.




                                                                             7 

        PROGRAM AREAS
        The N a t i o n a l Cancer I n s t i t u t e h a s announced a g o a l and o b j e c t i v e s for a c h i e v i n g a
        r e d u c t i o n o f 50 % i n t h e cancer m o r t a l i t y r a t e by t h e y e a r 2000 (Greenwald, P . ,
        Sondik, E . J . Cancer Control O b j e c t i v e s For t h e Nation:               1985 - 2000. N C I Monograph
        No.2, 1986)
                                                                                                                                                       I
**Y 	   Cancer C o n t r o l Program a r e a s a p p r o p r i a t e f o r r e s e a r c h g r a n t s i n c l u d e HUMAN
        INTERVENTION RESEARCH i n t h e f o l l o w i n g areas:
           o 	 P r e v e n t i o n (chemoprevention;             d i e t and n u t r i t i o n ; e a r l y
               detection1
           o 	 Community oncology (improving t h e a p p l i c a t i o n o f p a t i e n t
                management and c o n t i n u i n g care r e s e a r c h advances i n t o
                community s e t t i n g s 1
           o 	 Health promotion s c i e n c e s (modifying p e r s o n a l , s o c i a l ,
               l i f e s t y l e and h e a l t h care system f a c t o r s which c o n t r i b u t e
               t o c a n c e r p r e v e n t i o n and c o n t r o l )
           o    Smoking p r e v e n t i o n and c e s s a t i o n
           o    Cancer c o n t r o l o p e r a t i o n s r e s e a r c h and e v a l u a t i o n
           o 	 C o n t r o l a p p l i c a t i o n s r e s e a r c h ( a d a p t a t i o n o f s t a t e and l o c a l
               h e a l t h agency d a t a b a s e s f o r c a n c e r c o n t r o l p l a n n i n g
               and e v a l u a t i o n ; f e a s i b i l i t y t e s t i n g o f i n t e r v e n t i o n s i n
               community s e t t i n g s 1
           o 	 Applied epidemiology ( u s i n g epidemiologic methods t o
               determine t h e a s s o c i a t i o n between exposure t o an
               INTERVENTION and i t s impact on d i s e a s e )
           o 	 Planning,  epidemiologic and survey s t u d i e s aimed a t
                developing cancer control interventions
        EXCLUSIONS
        Animal s t u d i e s , and s t u d i e s t o determine t h e e f f i c a c y of chemotherapy, s u r g e r y ,
        r a d i o t h e r a p y , and o t h e r primary t r e a t m e n t i n t e r v e n t i o n s are n o t c o n s i d e r e d c a n c e r
*w      c o n t r o l r e s e a r c h under t h i s RFA.
        ELIGIBILITY
        I n v e s t i g a t o r s are e l i g i b l e t o apply f o r a small g r a n t t o s u p p o r t r e s e a r c h on a 

        c a n c e r c o n t r o l t o p i c i f t h e y a r e i n t e r e s t e d i n conducting e x p l o r a t o r y s t u d i e s i n 

        c a n c e r c o n t r o l r e s e a r c h . T h i s i n c l u d e s e s t a b l i s h e d r e s e a r c h e r s from o t h e r 

        d i s c i p l i n e s , new i n v e s t i g a t o r s , and i n v e s t i g a t o r s c u r r e n t l y e n r o l l e d i n an 

        a c c r e d i t e d d o c t o r a l d e g r e e program. D i s s e r t a t i o n r e s e a r c h p r o p o s a l s are a c c e p t a b l e 

        from e i t h e r t h e s t u d e n t or t h e s t u d e n t ' s a d v i s o r i f t h a t i s t h e i n s t i t u t i o n ' s 

        policy. 

        The o n l y INELIGIBLE a p p l i c a n t s are t h o s e i n d i v i d u a l s who are or have p r e v i o u s l y been 

        a P r i n c i p a l I n v e s t i g a t o r on a n N C I funded CANCER CONTROL g r a n t or c o n t r a c t , or a 

        p a i d s t a f f member on a n N C I funded CANCER CONTROL g r a n t or c o n t r a c t f o r more t h a n 

        TWO y e a r s . 

        MECHANISMS OF SUPPORT 

        T o t a l c o s t s ( d i r e c t p l u s i n d i r e c t c o s t s ) must n o t exceed $35,000. The d u r a t i o n of 

        s u p p o r t i s one y e a r b u t may be l o n g e r (up t o two y e a r s ) i f t h e $35,000 t o t a l c o s t 

        l i m i t i s n o t exceeded f o r t h e e n t i r e g r a n t p e r i o d . 

        INQUIRIES 

        Copies o f t h e complete RFA and a d d i t i o n a l i n f o r m a t i o n may be o b t a i n e d from e i t h e r 

        person noted below: 

        C a r l o s E . Caban, Ph.D. 

        Program D i r e c t o r for Cancer C o n t r o l Research 

        Cancer C o n t r o l A p p l i c a t i o n s Branch 

        D i v i s i o n of Cancer P r e v e n t i o n and C o n t r o l 

        N a t i o n a l Cancer I n s t i t u t e 

        B l a i r B u i l d i n g , Room 4A01 

 wv 	   9000 R o c k v i l l e Pike
        Bethesda, Maryland 20892-4200
        Telephone:            ( 3 0 1 ) 427-8735
                                                                              a
          David C . Poskanzer, M.D. 

          Cancer C o n t r o l S c i e n c e Program

          D i v i s i o n of Cancer P r e v e n t i o n and C o n t r o l 

          N a t i o n a l Cancer I n s t i t u t e 

          B l a i r B u i l d i n g , Room 4A01 

          9000 R o c k v i l l e P i k e 

*. ,
 .a
 ,
          Bethesda, Maryland 20892-4200 

          Telephoner            ( 3 0 1 ) 427-8788 

          P r o s p e c t i v e a p p l i c a n t s a r e s t r o n g l y encouraged t o d i s c u s s t h e i r i d e a s w i t h a Program

          D i r e c t o r t o d e t e r m i n e whether t h e y f i t w i t h i n t h e d e f i n i t i o n and program g u i d e l i n e s 

          o f c a n c e r c o n t r o l . PLEASE CONTACT THE P O R M DIRECTOR(s1 BEFORE SUBMITTING AN

                                                                              RGA
          APPLICATION I F THERE I S ANY UNCERTAINIY ABOUT MEETING THE CRITERIA. 


          MTA-BASED INTERVENTIONS FOR CANCER CONTROL 

          RFA AVAILABLE8            87-CA-16 

          P.T. 34;        K . W . 1014002, 0730050, 0730070, 0403004 

          N a t i o n a l Cancer I n s t i t u t e 

          Letter o f i n t e n t r e c e i p t d a t e : J a n u a r y 8, 1987 

          A p p l i c a t i o n R e c e i p t D a t e r March 5, 1987 

          The D i v i s i o n o f Cancer P r e v e n t i o n and C o n t r o l (DCPC) o f t h e N a t i o n a l Cancer 

          I n s t i t u t e ( N C I ) i n v i t e s grant a p p l i c a t i o n s i n support of p r o j e c t s t h a t w i l l s e r v e a s 

          models o f d a t a u s e i n t h e p l a n n i n g and e v a l u a t i o n o f s t a t e w i d e c a n c e r p r e v e n t i o n and 

          c o n t r o l programs. 

          RESEARCH GOALS AND SCOPE 

          T h i s RFA i s d e s i g n e d t o s t i m u l a t e t h e development o f c a n c e r p r e v e n t i o n and c o n t r o l 

          i n t e r v e n t i o n programs on t h e s t a t e and l o c a l l e v e l based on a thorough a n a l y s i s and 

          evaluation,of t h e v a r i e t y of data sources r e l a t e d t o cancer control t h a t e x i s t i n 

          t h e s t a t e . The t h r e e - p h a s e d p r o j e c t i n c l u d e s ( 1 ) i d e n t i f i c a t i o n and e v a l u a t i o n o f 

          e x i s t i n g p o p u l a t i o n - s p e c i f i c d a t a s o u r c e s r e l a t e d t o c a n c e r c o n t r o l and t h e 

          development or m o d i f i c a t i o n o f a c a n c e r c o n t r o l p l a n , ( 2 ) i n i t i a t i o n o f new or 

          m o d i f i c a t i o n o f e x i s t i n g c a n c e r p r e v e n t i o n and c o n t r o l programs a s s p e c i f i e d i n t h e 

          p l a n , and ( 3 ) a p e r i o d f o r e v a l u a t i o n o f p r o c e s s and outcome. 

   wv 

          ELIGIBILITY
          A p p l i c a n t s must be s t a t e or t e r r i t o r i a l h e a l t h departments. Local h e a l t h 

          departments or a g e n c i e s w i t h i n t h e j u r i s d i c t i o n with primary r e s p o n s i b i l i t y f o r 

          cancer c o n t r o l a c t i v i t i e s may a p p l y through t h e s t a t e or t e r r i t o r i a l h e a l t h 

          department. H e a l t h departments c u r r e n t l y funded under t h e N C I g r a n t "Cancer C o n t r o l 

          T e c h n i c a l Development i n H e a l t h Agencies" a r e n o t e l i g i b l e t o a p p l y f o r t h i s g r a n t . 

          MECHANISM OF SUPPORT 

          Funding i s l i m i t e d t o a maximum o f f i v e y e a r s . Approximately e i g h t awards a r e 

          a n t i c i p a t e d f o r Phase I w i t h f o u r c o n t i n u i n g i n t o Phases I1 and 111, depending on 

          t h e a v a i l a b i l i t y and q u a l i t y o f a p p l i c a t i o n s and f u n d i n g . 

          INQUIRIES 

          Copies of t h e complete RFA and a d d i t i o n a l i n f o r m a t i o n may b e o b t a i n e d from: 

          D r . L e s l i e Boss, Program D i r e c t o r 

          Cancer C o n t r o l A p p l i c a t i o n s Branch 

          Cancer C o n t r o l S c i e n c e Program

          N a t i o n a l Cancer I n s t i t u t e 

          B l a i r B u i l d i n g , Room 4A01 

          9000 R o c k v i l l e P i k e 

          Bethesda, MD 20892-4200 

          Telephone ( 3 0 1 ) 427-8684 





                                                                              9
       SPECIALIZED          CENTERS OF RESEARCH I N ADULT RESPIRATORY F A I L W
       RFA AVAILABLE:            87-HL-01-L
       P.T. 34;        K.W. 0715165, 0745020, 0745055, 0415000, 0710030
‘‘-N   N a t i o n a l Heart, Lung, and Blood I n s t i t u t e

       A p p l i c a t i o n R e c e i p t Date:   September 15, 1987 

       The D i v i s i o n of Lung Diseases i n v i t e s new or competing c o n t i n u a t i o n a p p l i c a t i o n s f o r 

       g r a n t s t o s u p p o r t S p e c i a l i z e d C e n t e r s o f Research (SCORs) i n Adult R e s p i r a t o r y 

       F a i l u r e . T h i s SCOR program i s p a r t o f t h e comprehensive r e s e a r c h program s u p p o r t e d 

       by t h e D i v i s i o n t o improve t h e outcome i n p a t i e n t s w i t h a d u l t r e s p i r a t o r y f a i l u r e , a 

       c o n d i t i o n a s s o c i a t e d w i t h a h i g h m o r t a l i t y rate. The purpose o f t h e SCOR program is 

       t o f o s t e r a concerted, multidisciplinary research e f f o r t t h a t involves basic 

       i n v e s t i g a t i o n s , b u t p l a c e s a major emphasis on t h e c l i n i c a l problems r e l e v a n t t o t h e 

       p r e v e n t i o n , e a r l y d i a g n o s i s , and management of t h i s d i s o r d e r . 

       A l e t t e r o f i n t e n t is r e q u e s t e d by May 15, 1987, and t h e d e a d l i n e for r e c e i p t o f 

       a p p l i c a t i o n s is September 15, 1987. It i s expected t h a t awards w i l l be made i n 

       December, 1988. A p p l i c a t i o n s r e c e i v e d i n r e s p o n s e t o t h i s announcement w i l l take 

       p a r t i n a s i n g l e competition. 

       Requests for c o p i e s o f t h i s RFA should be a d d r e s s e d t o : 

       Suzanne S. Hurd, Ph.D. 

       D i r e c t o r , D i v i s i o n o f Lung D i s e a s e s 

       N a t i o n a l Heart, Lung, and Blood I n s t i t u t e 

       Westwood B u i l d i n g      -    Room 6A16 

       National I n s t i t u t e s of Health 

       Bethesda, Maryland 20892 

       Telephone: (301) 496-7208 





                                                                     10          *U. S. GOVERNMENT PRINTING OFFICE8 1986-181-289140021

								
To top